Wells Fargo & Company Allovir, Inc. Transaction History

Wells Fargo & Company

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.64 - $0.78 $1,468 - $1,790	2,295 Added 14.37%	18,263 $13,000
Q4 2023 Feb 09, 2024	BUY	$0.68 - $2.39 $2,108 - $7,411	3,101 Added 24.1%	15,968 $10,000
Q3 2023 Nov 13, 2023	SELL	$2.15 - $3.64 $7,157 - $12,117	-3,329 Reduced 20.55%	12,867 $27,000
Q2 2023 Aug 15, 2023	BUY	$3.17 - $5.82 $32,879 - $60,365	10,372 Added 178.09%	16,196 $55,000
Q1 2023 May 12, 2023	BUY	$3.94 - $7.05 $22,158 - $39,649	5,624 Added 2812.0%	5,824 $22,000
Q4 2022 Feb 13, 2023	SELL	$4.7 - $9.98 $2,617 - $5,558	-557 Reduced 73.58%	200 $1,000
Q3 2022 Nov 14, 2022	SELL	$4.13 - $8.79 $850 - $1,810	-206 Reduced 21.39%	757 $6,000
Q2 2022 Aug 12, 2022	SELL	$3.26 - $7.06 $534 - $1,157	-164 Reduced 14.55%	963 $3,000
Q1 2022 May 16, 2022	SELL	$6.75 - $13.52 $74,391 - $149,003	-11,021 Reduced 90.72%	1,127 $8,000
Q4 2021 Feb 14, 2022	BUY	$12.94 - $25.99 $156,962 - $315,258	12,130 Added 67388.89%	12,148 $157,000
Q3 2021 Nov 15, 2021	SELL	$16.97 - $25.06 $291,917 - $431,082	-17,202 Reduced 99.9%	18 $0
Q2 2021 Aug 16, 2021	BUY	$19.44 - $25.06 $334,406 - $431,082	17,202 Added 95566.67%	17,220 $340,000
Q1 2021 May 13, 2021	SELL	$20.81 - $45.5 $217,277 - $475,065	-10,441 Reduced 99.83%	18 $0
Q4 2020 Feb 09, 2021	SELL	$23.94 - $46.81 $90,852 - $177,643	-3,795 Reduced 26.62%	10,459 $402,000
Q3 2020 Nov 05, 2020	BUY	$21.05 - $42.7 $300,046 - $608,645	14,254 New	14,254 $392,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $51.2M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.